Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Wix.Com Ltd — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B), while Wix.Com Ltd trades at $73.17 (market cap $3.11B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.4× Wix.Com Ltd's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Wix.Com Ltd for 62 Days on average.
| SYRE | WIX | |
|---|---|---|
Market Cap | $7.35B | $3.11B |
Volume | 1,624,631 | 736,895 |
Sector | Health | Technology |
52-Week High | $108.92 | $145.54 |
52-Week Low | $22.18 | $40.43 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $6.35B | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
WIX trades at $71.74, down 3.28% today, amid a bearish technical signal and negative net cash flow. Revenue grew to $1.99B in 2025, but net income fell to $50.65M with a negative margin. Analyst consensus is bullish with a $77.00 price target, though recent class action lawsuits have dampened sentiment.
The outlook is mixed: strong revenue growth and analyst support offer upside, but profitability concerns, litigation risks, and negative equity pose significant challenges. Investors should weigh the high P/E ratio against potential operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
